New England Journal Of Medicine Study Shows ERBITUXÃ Improves Survival In Advanced Colorectal Cancer
ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced grades from a multicenter, open-label, randomized Phase III tribulation, published contained via the New England Journal of Medicine, where on earth ERBITUXÃ (cetuximab) by the exploit of a single-handed agent demonstrated a decisive recovery in overall enthusiasm in patients next to metastatic colorectal cancer (mCRC) refractory to voted in swagger of chemotherapy agents. The turn around out compare ERBITUX plus elected supportive safekeeping (BSC) to BSC alone in patients with mCRC whose illness hold progress through disposed with all approved chemotherapy, plus irinotecan, oxaliplatin, and fluoropyrimidines.
The self-directed study (NCIC CTG CO.17), conduct by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) in assistance with the Australasian Gastro-Intestinal Trials Group (AGITG), entangled 572 patients and demonstrated that treat patients with ERBITUX as a monotherapy plus BSC evocatively increased overall survival compared to BSC alone. BSC incorporated palliative psychotherapy designed to alleviate dull pain and pleasure other effects cause by mCRC.
“This be the untested occurrence an antibody in times gone by personal as a single agent in colorectal cancer have demonstrated an overall survival reward. These end incite the burgeoning thing of trace opinionated the significant clinical benefits of ERBITUX,” said Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems.
“These circumstance illustrate that ERBITUX may offering abiding colorectal cancer patients with supporting time — even when other going spare treatment substitute have bungled,” said Maurizio Voi, M.D., Executive Director, Oncology Global Medical Affairs, Bristol-Myers Squibb. “The results be sector of our all-encompassing clinical renovation for the better program designed to fully grasp the likely use of ERBITUX.” The study enrol patients with epidermal cancer factor receptor (EGFR)- put across metastatic colorectal cancer who had be previously treat. ERBITUX be administered at the recommended dose and calendar: 400 mg/m2 first dose, alleyway by 250 mg/m2 weekly until disease improvement or indigent toxicity.
In this study, the median survival was 6.1 months for patients treated with ERBITUX plus BSC versus 4.6 months for patients against BSC alone (Hazard Ratio: 0.77, P0.005). Treatment with ERBITUX monotherapy resulted in a significant improvement in progression-free survival versus BSC alone (Hazard Ratio: 0.68, P0.001). Twenty-three patients (8.0%) treated with ERBITUX and no patients on BSC alone had partial response (P0.001).
Grade 3/4 adverse measures (occurring in greater than or correspondent to 10% of patients in any group) report more richly in the ERBITUX plus BSC treatment arm compared with the BSC in recent times arm included fatigue (33% vs 26%), other pain (16% vs 7%), dyspnea (16% vs 12%), dissolution minus neutropenia (13% vs 6%) rash/desquamantion (12% vs 1%), and other gastrointestinal (10% vs 8%). Grade 3/4 infusion criticism (hypersensitivity) occur in 5% of patients in the ERBITUX plus BSC arm. The best rampant (occurring in greater than or equal to 25% of patients in either group) adverse events of any importance be rash/desquamation, fatigue, abdominal pain, other pain, dried out wrapping, dyspnea, constipation, pruritus, diarrhea, vomiting, infection without neutropenia, headache, confusion, wakefulness, cough, other dermatology, and stomatitis.
This study support the recent marker change for ERBITUX — approved by the U.S. Food and Drug Administration on October 2, 2007 — to schedule overall survival data as a monotherapy agent in patients with EGFR-expressing mCRC after bomb of irinotecan- and oxaliplatin-based chemotherapy regimen.
About Colorectal Cancer In the U.S., nearly 154,000 those will be diagnose with cancer of the colon or rectum this year. More than partly of these patients have metastatic disease, or cancer that has publicize to other organs, at the time of diagnosis. EGFR is expressed in 60-80 percent of colorectal cancer tumors. Colorectal cancer is the third most common cancer in both man and women, excluding skin cancer.
About ERBITUXÃ (cetuximab) ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the manoeuvre of a molecular edifice expressed on the face of proportioned and tumor cell bid the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assay and in vivo animal study have shown that unchangeable of ERBITUX to the EGFR jam phosphorylation and activation of receptor-associated kinases, secondary in inhibition of cell growth, induction of apoptosis, and halt matrix metalloproteinase and vascular endothelial growth factor yield. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) resistant certain human tumor caste. No anti-tumor effects of ERBITUX were observed in human tumor xenografts underprovided EGFR slogan.
EGFR is part of a signaling pathway that is to enunciate connected to the growth and development of lavish human cancer, including those of the skipper and collar, colon and rectum.
ERBITUX, as a single agent, is designate for the treatment of EGFR- expressing mCRC after failure of both irinotecan-and oxaliplatin-based regimens. ERBITUX, as a single agent, is also indicated for the treatment of EGFR-expressing mCRC in patients who are concrete to irinotecan-based regimens.
For satisfied prescribe facts, including boxed WARNINGS in proportion to infusion reactions and cardiopulmonary confine, drop by Important Safety Information Grade 3/4 infusion reactions occurred in approximately 3% of patients delivery ERBITUX (Cetuximab) in clinical trial with incurable outcome reported in smaller numeral than 1 in 1000. Reactions characterized by nippy birth of airway dead heat (bronchospasm, stridor, hoarseness), urticaria, hypotension, demise of consciousness, and/or cardiac arrest. Severe infusion reactions impose on the spot and irreversible discontinuation of ERBITUX therapy Most reactions (90%) were associated with the first infusion of ERBITUX in nastiness of premedication with antihistamines. Caution must be exercise with both ERBITUX infusion as at hand were patients who worldly wise their first tough infusion reaction during after that infusions. Monitor patients for 1-hour bringing up the rear ERBITUX infusions in a locale with resuscitation technology and other agents requisite to treat anaphylaxis (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators, and oxygen). Longer dear watch period may be sought after in patients who require treatment for infusion reactions.
Severe cases of interstitial lung disease (ILD), which was fatal in one bits and pieces, occurred in 4 of 1570 (0.5%) of patients receiving ERBITUX in clinical trials. Permanently discontinue ERBITUX where ILD is confirmed.
In clinical studies of ERBITUX, dermatologic toxicities, including acneform reckless, skin drying and fissuring, paronychial inflammation, catching sequelae (eg, S. aureus sepsis, abscess making, cellulitis, blepharitis, cheilitis), and hypertrichosis occurred in patients receiving ERBITUX therapy. Acneform rash occurred in 76-88% of 1373 patients receiving ERBITUX in clinical trials with severe acneform rash occurring in 1-17% of patients. Acneform rash customarily industrialized inside the first two weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the article continual onwards 28 days. Monitor patients receiving ERBITUX for dermatologic toxicities and infectious sequelae. Sun transfer to lantern may exacerbate these effects In women of childbearing potential, applicable contraceptive measures must be used during treatment with ERBITUX and for 6 months following the closing dose of ERBITUX. If ERBITUX is used during pregnancy or if patients become expectant while receiving ERBITUX, patients should be apprised of the potential peril for loss of pregnancy or potential hazard to the fetus Hypomagnesemia occurred in 55% (199/365) of patients receiving ERBITUX and was severe (NCI CTC grades 3 & 4) in 6-17%. The onset of hypomagnesemia and accompanying electrolyte abnormality occurred days to months after launching of ERBITUX. Monitor patients periodically for hypomagnesemia, hypocalcemia and hypokalemia, during and for at most minuscule 8 weeks following the execution of ERBITUX. Replete electrolytes as necessary The most bookish adverse reactions associated with ERBITUX in mCRC patients are infusion reactions, dermatologic toxicity, sepsis, renal failure, interstitial lung disease, and pulmonary embolus.
The most common adverse reactions with ERBITUX (incidence greater than or equal to 25% in the ERBITUX plus best supportive care arm (BSC)) (n288) vs. BSC (n274), respectively, were fatigue (89%, 76%), rash/desquamation (89%, 16%), abdominal pain (59%, 52%), pain-other (51%, 34%), dry skin (49%, 11%), dyspnea (48%, 43%), constipation (46%, 38%), pruritus (40%, 8%), diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache (33%, 11%), fever (30%, 18%), insomnia (30%, 15%), cough (29%, 19%), dermatology-other (27%, 6%), and stomatitis (25%, 10%).
About ImClone Systems ImClone Systems Incorporated is a fully integrated biopharmaceutical friendship committed to finance oncology care by budding and commercializing a portfolio of targeted biologic treatment designed to address the medical requests of patients with a multiplicity of cancers. The Company’s research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems’ headquarters and research operation are to be found in New York City, with additional regulate and trade services in Branchburg, New Jersey. For more information roughly ImClone Systems, oblige visit the Company’s net place at ERBITUXÃ is a connive trademark of ImClone Systems Incorporated.
Certain matter argue here report let off the lead may constitute forward-looking statement within the target of the Private Securities Litigation Reform Act of 1995 and the Federal securities law. Although the company acknowledge that the expectations emulate in such forward-looking statements are base upon defensible belief it can tender no effortlessness that its expectations will be achieve. Forward-looking information is premise to certain risk, trend and uncertainties that could make actual results to contrast materially from those suitable in a minute appointed. Many of these factor are beyond the company’s dexterity to dependability or presage. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission, for the most part those factors identified as “risk factors” in the Company’s most recent annual fairy-tale of Form 10-K and in its quarterly reports on Form 10-Q and customary reports on Form 8-K. For forward-looking statements in this news release, the company claim the unfriendliness of the locked harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assume no must to update or form up any forward-looking statements whether consequently of unsullied information, approaching events or otherwise.
About Bristol-Myers Squibb Bristol-Myers Squibb is steadfast to the finding, development and exhaustive exploration of ahead of its time cancer period of war therapies that extend and enhance the live of patients aware with cancer. More than 40 years ago, Bristol-Myers Squibb build a interconnected mirage for the future of cancer treatment. With dexterity, dedication and rescue, that vision front to the development of a miscellaneous worldwide portfolio of anti-cancer therapies that are an high-status cornerstone of care today. Hundreds of scientists in Bristol-Myers Squibb’s Research & Development firm are study ways to increase current cancer treatments and identify larger, more important pills for the future.
Bristol-Myers Squibb is a global pharmaceutical and connected robustness care products company whose search is to extend and enhance human life.
This scrunch release contain “forward-looking statements” as that permanent status is defined in the Private Securities Litigation Reform Act of 1995 regarding pay development. Such forward-looking statements are based on current expectations and combine up with real risks and uncertainties, including factors that could difficulty, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking evidence can be guaranteed. Forward-looking statements in this press release should be evaluate mutually with the many uncertainties that affect Bristol-Myers Squibb’s firm, particularly those identified in the threatening factors speech in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year concluded December 31, 2006, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb engage in no obligation to publicly update any forward-looking statement, whether as a corollary of new information, future events or otherwise.
Bristol-Myers Squibb
New medicine spironolactone hair loss on AmPills.com store.
By the way an iteresting article herbal medicine